. 2020 Jul 27;120(10):1357–1370. doi: 10.1055/s-0040-1714279
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (
https://creativecommons.org/licenses/by-nc-nd/4.0/
).
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
Fig. 1.
Schematic comparison of ( A ) physiologic hemostasis and ( B ) hemostasis in hemophilia A under treatment with emicizumab.